ArticleVirchows Archiv : an international journal of pathology2026
Addressing HER2 IHC scoring discrepancies in endometrial serous carcinoma: a comparative analysis with reflex ISH.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HER2 overexpression and amplification occur in a subset of endometrial serous carcinomas (ESC) and carcinosarcomas, but HER2 testing remains unsettled due to the lack of tumor-specific guidelines. We retrospectively evaluated 113 tumors with serous morphology (95 ESC, 4 mixed carcinomas, 13 carcinosarcomas) diagnosed between 2001 and 2022 at two tertiary centers. HER2 immunohistochemistry was assessed using four scoring systems: ASCO/CAP 2007 breast, ASCO/CAP 2023 breast, ASCO/CAP/ASCP 2016 gastric, and an ESC-specific algorithm. All equivocal and discordant cases underwent in situ hybridization (ISH). HER2 positivity ranged from 15% with the 2007 breast and ESC-specific systems to 20% with the 2023 breast and 24% with the gastric criteria, and it was significantly associated with patient age > 70 years (p = 0.016). Concordance was excellent between the 2007 breast and ESC-specific systems (K = 0.98), good between the 2023 breast and 2007/ESC systems (K = 0.71-0.73), and excellent between the 2023 breast and gastric criteria (K = 0.95). Eight discordant tumors were resolved by ISH, confirming ERBB2 amplification in five. Intratumoral heterogeneity was observed in 13 cases (12%), including one carcinosarcoma with focal gene amplification. The prevalence of HER2-low tumors varied markedly, from 16 (14%) with gastric criteria to 26 (23%) with ESC-specific scoring. These findings demonstrate that the choice of scoring system substantially impacts HER2 classification in ESC. While 2007 breast and ESC-specific criteria remain the only ones validated for trastuzumab, gastric criteria are required for trastuzumab-deruxtecan eligibility. Standardized, therapy-specific algorithms integrating IHC and ISH are essential to optimize patient selection, including candidates with HER2-low tumors.
Indexed as
Identifiers
41447402What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.